TW202322818A - Lpxc抑制劑及其用途 - Google Patents

Lpxc抑制劑及其用途 Download PDF

Info

Publication number
TW202322818A
TW202322818A TW111136418A TW111136418A TW202322818A TW 202322818 A TW202322818 A TW 202322818A TW 111136418 A TW111136418 A TW 111136418A TW 111136418 A TW111136418 A TW 111136418A TW 202322818 A TW202322818 A TW 202322818A
Authority
TW
Taiwan
Prior art keywords
pharmaceutically acceptable
compound
alkyl
acceptable salt
phenyl
Prior art date
Application number
TW111136418A
Other languages
English (en)
Chinese (zh)
Inventor
敏 滕
Original Assignee
美商福吉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商福吉醫療公司 filed Critical 美商福吉醫療公司
Publication of TW202322818A publication Critical patent/TW202322818A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW111136418A 2021-09-28 2022-09-26 Lpxc抑制劑及其用途 TW202322818A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163249166P 2021-09-28 2021-09-28
US63/249,166 2021-09-28

Publications (1)

Publication Number Publication Date
TW202322818A true TW202322818A (zh) 2023-06-16

Family

ID=85783440

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111136418A TW202322818A (zh) 2021-09-28 2022-09-26 Lpxc抑制劑及其用途

Country Status (12)

Country Link
US (2) US12187754B2 (https=)
EP (1) EP4408853A4 (https=)
JP (1) JP2024536864A (https=)
KR (1) KR20240097839A (https=)
CN (1) CN118302429A (https=)
AR (1) AR127139A1 (https=)
AU (1) AU2022357226A1 (https=)
CA (1) CA3233328A1 (https=)
IL (1) IL311588A (https=)
MX (1) MX2024003859A (https=)
TW (1) TW202322818A (https=)
WO (1) WO2023055686A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019345150A1 (en) * 2018-09-20 2021-05-13 Blacksmith Medicines, Inc. Antibacterial compounds
TW202322818A (zh) 2021-09-28 2023-06-16 美商福吉醫療公司 Lpxc抑制劑及其用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US5543534A (en) 1994-12-29 1996-08-06 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
US6875619B2 (en) 1999-11-12 2005-04-05 Motorola, Inc. Microfluidic devices comprising biochannels
US20050009101A1 (en) 2001-05-17 2005-01-13 Motorola, Inc. Microfluidic devices comprising biochannels
ES2572030T3 (es) 2001-08-10 2017-07-19 Shionogi & Co., Ltd. Agente antiviral
AR037641A1 (es) 2001-12-05 2004-11-17 Tularik Inc Moduladores de inflamacion
WO2003063831A2 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Immediate release dosage forms containing solid drug dispersions
KR101076018B1 (ko) 2003-01-08 2011-10-21 유니버시티 오브 워싱톤 항균제
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
WO2005110399A2 (en) 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
WO2006028523A2 (en) 2004-04-29 2006-03-16 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO USDC Technology Transfer Office Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors
WO2008027466A1 (en) 2006-08-31 2008-03-06 Schering Corporation Hydantoin derivatives useful as antibacterial agents
BRPI0720547A2 (pt) 2006-10-05 2014-05-06 Janssen Pharmaceutica Nv Inibidores de metaloprotease derivada de heterocíclico
TWI519508B (zh) 2007-06-12 2016-02-01 Achaogen Inc 抗菌劑
US8871728B2 (en) 2007-06-29 2014-10-28 Georgia Tech Research Corporation Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof
WO2010059838A2 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects
IT1392249B1 (it) 2008-11-28 2012-02-22 Univ Degli Studi Urbino Derivati di [(3-idrossi-4-piron-2-il)metil]-amina e loro uso come farmaci anti-neoplastici
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
AU2012273100B2 (en) 2011-06-19 2017-05-25 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
US9394260B2 (en) 2012-04-03 2016-07-19 Bristol-Myers Squibb Company Pyrimidinone carboxamide inhibitors of endothelial lipase
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
KR20150039832A (ko) 2012-08-06 2015-04-13 사피라 파르마슈티칼즈 게엠베하 디하이드록시피리미딘 탄산 유도체 및 바이러스성 질환의 치료, 개선 또는 예방에서의 이의 용도
AU2014209107B2 (en) 2013-01-28 2018-04-12 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections
US10647664B2 (en) 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds
WO2015085238A1 (en) 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibitors of lpxc
WO2015099107A1 (ja) 2013-12-26 2015-07-02 塩野義製薬株式会社 含窒素６員環誘導体およびそれらを含有する医薬組成物
BR112017004798A2 (pt) 2014-09-12 2017-12-12 Toyama Chemical Co Ltd composição farmacêutica que contém um derivado de ácido hidroxâmico ou um seu sal
DK3233843T3 (da) * 2014-12-16 2019-11-18 Novartis Ag Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
CN105777464B (zh) 2014-12-26 2020-09-29 中国科学院上海药物研究所 异羟肟酸衍生物及其制备方法和应用
WO2017083434A1 (en) 2015-11-09 2017-05-18 Forge Therapeutics, Inc. Pyrone based compounds for treating bacterial infections
EP3374350B1 (en) 2015-11-09 2022-01-05 Forge Therapeutics, Inc. Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
CN105669750B (zh) * 2016-03-01 2018-04-03 中国医学科学院医药生物技术研究所 新型锌离子螯合剂及其制备和在抗革兰氏阴性菌感染中的应用
US10889556B2 (en) 2016-03-08 2021-01-12 The Regents Of The University Of California Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease
MX388647B (es) 2016-12-23 2025-03-20 Intervet Int Bv Compuestos utiles para el tratamiento de una infeccion por mannheimia haemolytica o histophilus somni.
JPWO2018143162A1 (ja) * 2017-01-31 2019-11-14 富士フイルム富山化学株式会社 ヒドロキサム酸のプロドラッグである化合物またはその塩、凍結乾燥製剤、ＬｐｘＣ阻害剤および抗菌剤
WO2018208987A2 (en) 2017-05-10 2018-11-15 Forge Therapeutics, Inc. Antibacterial compounds
US11021471B2 (en) 2017-05-10 2021-06-01 Forge Therapeutics, Inc. Antibacterial compounds
WO2019086452A1 (en) 2017-10-31 2019-05-09 Idorsia Pharmaceuticals Ltd Antibacterial heteroaromatic compounds
BR112020016270A2 (pt) 2018-02-10 2020-12-15 Kbp Biosciences Co., Ltd. Composto atuando como antibióticos
AU2019345150A1 (en) 2018-09-20 2021-05-13 Blacksmith Medicines, Inc. Antibacterial compounds
WO2020102572A1 (en) 2018-11-14 2020-05-22 Forge Therapeutics, Inc. Antibacterial compounds
WO2021195258A1 (en) 2020-03-25 2021-09-30 Forge Therapeutics, Inc. Lpxc inhibitor, formulations, and uses thereof
WO2021195260A1 (en) 2020-03-25 2021-09-30 Forge Therapeutics, Inc. Lpxc inhibitor and methods of making
WO2022086920A1 (en) 2020-10-20 2022-04-28 Blacksmith Medicines, Inc. Glutaminyl-peptide cyclotransferase like (qpctl) protein inhibitors and uses thereof
EP4291550A4 (en) 2021-02-11 2025-01-22 Blacksmith Medicines, Inc. Antibacterial compounds
TW202322818A (zh) 2021-09-28 2023-06-16 美商福吉醫療公司 Lpxc抑制劑及其用途
TW202417432A (zh) 2022-08-10 2024-05-01 美商布萊克史密斯醫藥公司 抗菌化合物
WO2024036170A1 (en) 2022-08-10 2024-02-15 Blacksmith Medicines, Inc. Antibacterial compounds

Also Published As

Publication number Publication date
AU2022357226A1 (en) 2024-05-02
JP2024536864A (ja) 2024-10-08
MX2024003859A (es) 2024-05-21
US20250230180A1 (en) 2025-07-17
IL311588A (en) 2024-05-01
US12187754B2 (en) 2025-01-07
US20240270773A1 (en) 2024-08-15
KR20240097839A (ko) 2024-06-27
EP4408853A4 (en) 2025-08-27
WO2023055686A1 (en) 2023-04-06
AR127139A1 (es) 2023-12-20
CA3233328A1 (en) 2023-04-06
CN118302429A (zh) 2024-07-05
EP4408853A1 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
US20250230180A1 (en) Lpxc inhibitors and uses thereof
RU2690489C2 (ru) Ингибиторы лейкотриен а4-гидролазы
TW201431865A (zh) 硼酸衍生物及其治療用途
RU2696559C2 (ru) Ингибиторы лейкотриен а4-гидролазы
JP2011500845A (ja) カルバセフェムβ−ラクタム抗生物質
EP4155304B1 (en) Compound used as ret kinase inhibitor and application thereof
US20240002373A1 (en) Lpxc inhibitor and methods of making
TW201925201A (zh) 二氮雜二環辛烷衍生物
EP0839149B9 (fr) Derives de la galanthamine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
EP3750881A1 (en) Compound acting as antibiotics
WO2022173758A1 (en) Antibacterial compounds
US20240150298A1 (en) Antibacterial compounds
JP2025526728A (ja) 抗菌化合物
CN108003205B (zh) 氨基糖苷类衍生物及其制备方法和应用
JPH0438756B2 (https=)
US20240327458A1 (en) Macrocyclic peptidomimetic protease inhibitor and use thereof
EP0990654B1 (en) Substituted cyclobutylamine derivatives
US12391711B2 (en) Tetrahydrocannabinol derivatives, preparation method thereof and use thereof
EP4046998B1 (en) Sulfonylurea ring substituted monocyclic beta-lactam antibiotics
FR2995605A1 (fr) Derives de macrolides, leur preparation et leur application therapeutique.
CH654011A5 (fr) Phosphoramides, procede pour leur preparation et compositions pharmaceutiques les contenant.
WO2018081858A1 (en) Improved analogues of desferrioxamine b and their uses
FR3111544A1 (fr) Nouveaux composés dipeptidiques, leur procédé de fabrication et une nouvelle application thérapeutique de composés dipeptidiques.
HK40090211B (en) Compound used as ret kinase inhibitor and application thereof
KR20190088551A (ko) 루코트리엔 a4 하이드롤라제의 저해제